Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study).

"CONFLICTS OF INTEREST: Sang Wook Son, Ki-Heon Jeong, Jiyoung Ahn, Il-Hwan Kim, Un Ha Lee, Joo Yeon Ko, and Kwang Joong Kim report no conflict of interest. Dong Hyun Kim has received research funding and speaker fees from AbbVie, Inc., Janssen Pharmaceuticals, Inc., Novartis Pharmaceutical Corporation, andLilly. Eun-So Lee received grants for clinical research from AbbVie, Inc., Celgene Corporation, Cell Biotech, Lilly, Janssen Pharmaceuticals, Inc., and Servier; served as an advisor or consultant for AbbVie, Inc., Celgene Corporation, Galderma Korea, Janssen Pharmaceuticals, Inc., Lilly, and Novartis Pharmaceutical Corporation. Hai-Jin Park has served as an advisor for Janssen Pharmaceuticals, Inc., and participated in clinical trials for Eli Lilly and Bristol-Myers Squibb. Byung-Soo Kim has served as a scientific adviser or clinical study investigator for Abbvie, Astellas, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Inc., Kyowa Hakko Kirin, LEO Pharma, Novartis, Regeneron, and Sanofi.: Javed Rashid and Jin Ju Kim are current and former employees of Abbvie, Inc., respectively, and may hold stock or stock options."

"FUNDING SOURCE: This study was funded by AbbVie, Inc. AbbVie, Inc. was responsible for the study design and data interpretation, and has reviewed and approved this manuscript for submission."

"Conclusion: Adalimumab improved QoL and was well-tolerated in Korean patients with moderate to severe psoriasis, as demonstrated in a real-world setting. Clinical trial registration number (clinicaltrials.gov: NCT03099083)."